

Supplementary Table 1: Intraclass correlation coefficient stratified by therapeutic phase (induction* vs maintenance).

	ICC		Differences	
	ICC	IC 95%	average	IC 95%
<i>in house-Sanquin</i>				
Induction	0.660	0.397-0.808	-7.70	-10.56 -4.84
Maintenance	0.607	0.431-0.728	.08	-.96 1.12
<i>in house-QB</i>				
Induction	0.857	0.747-0.919	-3.30	-4.71 -1.89
Maintenance	0.846	0.777-0.893	-.60	-1.24 .05
<i>In house-r-biopharm</i>				
Induction	0.842	0.719-0.911	-.12	-1.35 1.10
Maintenance	0.877	0.822-0.915	-1.33	-1.91 -.74
Sanquin-QB				
Induction	0.842	0.720-0.911	4.40	2.24 6.56
Maintenance	0.860	0.797-0.903	-.68	-1.38 .03
Sanquin-r-biopharm				
Induction	0.622	0.330-0.787	7.58	4.74 10.41
Maintenance	0.791	0.698-0.856	-1.41	-2.25 -.57
QB-r-biopharm				
Induction	0.897	0.818-0.942	3.18	2.08 4.28
Maintenance	0.930	0.898-0.951	-.73	-1.20 -.26

* samples taken before the first IFX infusion were excluded from this analysis.

Supplementary Table 2: Qualitative comparison between the CT-P13 quantification assays using the therapeutic interval 3-7 (i.e., <3, [3-7[, and ≥7) and stratified by therapeutic phase (induction* vs maintenance).

	Accuracy	Kappa [CI 95%]
<i>in house</i>		
Sanquin	75%	0.597 [0.496-0.698]
Induction	84%	0.670 [0.441-0.899]
Maintenance	68%	0.578 [0.468-0.688]
QB	80%	0.776 [0.177-0.840]
Induction	89%	0.785 [0.587-0.982]
Maintenance	71%	0.676 [0.585-0.767]
r-biopharm	77%	0.752 [0.685-0.819]
Induction	91%	0.817 [0.630-1.000]
Maintenance	67%	0.639 [0.545-0.733]
Sanquin		
QB	80%	0.671 [0.577-0.766]
Induction	92%	0.857 [0.725-0.989]
Maintenance	71%	0.653 [0.548-0.758]
r-biopharm	77%	0.622 [0.522-0.721]
Induction	92%	0.818 [0.637-0.999]
Maintenance	66%	0.570 [0.461-0.679]
QB		
r-biopharm	88%	0.874 [0.824-0.922]
Induction	98%	0.959 [0.878-1.000]
Maintenance	81%	0.799 [0.723-0.876]

* samples taken before the first IFX infusion were excluded from this analysis.